Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.45 |
| ▸ | NPY4R | P50391 | 3/20 | 0.41 |
| ▸ | NPY1R | P25929 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | CHRND | Q07001 | 5/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.39 |
| ▸ | CHRNG | P07510 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30759435 | 0.83 | ERAP2 (0.53) | LNPEPERAP2ERAP1NPY4RNPY1R | |
| SCHEMBL30759452 | 0.81 | ERAP2 (0.49) | LNPEPERAP2ERAP1NPY4RNPY1R | |
| SCHEMBL20489336 | 0.75 | NPY4R (0.52) | LNPEPERAP2ERAP1NPY4RNPY1R | |
| SCHEMBL30759487 | 0.75 | ERAP2 (0.67) | LNPEPERAP2ERAP1NPY4RNPY1R | |
| SCHEMBL1373292 | 0.71 | NPY4R (0.59) | LNPEPERAP2NPY4RNPY1RCHRND | |
| SCHEMBL1373290 | 0.71 | NPY4R (0.59) | LNPEPERAP2NPY4RNPY1RCHRND | |
| SCHEMBL15011504 | 0.71 | NPY4R (0.59) | LNPEPERAP2NPY4RNPY1RCHRND | |
| SCHEMBL29468059 | 0.71 | MME (0.60) | LNPEPERAP2ERAP1NPY4RNPY1R | |
| SCHEMBL2064607 | 0.71 | NPY4R (0.58) | NPY4RNPY1ROPRM1OPRD1NPY2R | |
| SCHEMBL2064604 | 0.71 | NPY4R (0.58) | NPY4RNPY1ROPRM1OPRD1NPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | LNPEP 967/4885ERAP2 3495/4885ERAP1 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.